Search clinical trials for: Busulfan/Cyclophosphamide

Total 3960 results

University of Leicester

Unknown

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

Neuroblastoma

Ireland, United Kingdom, France, Switzerland, Austria, Italy, Spain, Norway, Belgium, Denmark, Israel, Portugal, Sweden
Children's Cancer and Leukaemia Group

Unknown

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant

Neuroblastoma
Roswell Park Cancer Institute
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic-Myeloproliferative Diseases

United States
Fairview University Medical Center

Unknown

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Hemophagocytic Lymphohistiocytosis | Graft Versus Host Disease | Chediak-Higashi Syndrome | Virus-Associated Hemophagocytic Syndrome | X-Linked Lymphoproliferative Syndrome | Familial Erythrophagocytic Lymphohistiocytosis

United States
University Hospital, Clermont-Ferrand

Unknown

Allogeneic Hematopoietic Stem Cell Transplantation (RICE)

Hematologic Neoplasms | Solid Tumors

France
AIDS Malignancy Consortium
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Not yet recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

HIV Infection | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant... and other conditions

United States
University Hospital, Clermont-Ferrand

Unknown

Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma (Rice NK)

Neuroblastoma

France
Emory University

Completed

IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency

Severe Combined Immunodeficiency | T-Cell Immune Deficiency Diseases

United States
Shanghai General Hospital, Shanghai Jiao Tong University...
Changhai Hospital; Xiangya Hospital of Central South University; Tongji Hospital and other collaborators

Recruiting

CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML

High Risk Acute Myeloid Leukemia | Allogeneic Hematopoeitic Stem Cell Transplantation

China
Shanghai General Hospital, Shanghai Jiao Tong University...
Changhai Hospital; Xiangya Hospital of Central South University; Tongji Hospital and other collaborators

Recruiting

CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML

High Risk Acute Myeloid Leukemia | Allogeneic Hematopoeitic Stem Cell Transplantation

China
King's College Hospital NHS Trust

Terminated

Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin (FB-ATG)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United Kingdom
Northside Hospital, Inc.

Completed

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia

United States
European Organisation for Research and Treatment...

Unknown

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia

Leukemia

France, Belgium, Netherlands, Italy, Czech Republic, Portugal, Germany, Croatia, Turkey, Austria, Hungary
Fundacion Para La Investigacion Hospital La Fe

Unknown

Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen

Multiple Myeloma

Spain
Guenther Koehne

Suspended

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Myelodysplastic Syndromes | Graft Vs Host Disease | Graft-versus-host-disease

United States
Soonchunhyang University Hospital

Completed

Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL) (BME)

Non-Hodgkin's Lymphoma

Korea, Republic of
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University and other collaborators

Completed

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Sickle Cell Disease | Hemoglobinopathies | Thalassemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma

United States
The Korean Society of Pediatric Hematology Oncology

Unknown

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML

Acute Myeloid Leukemia

Korea, Republic of
Peking University People's Hospital

Recruiting

ATG Plus Low-dose PT-Cy for GVHD Prevention

Hematologic Malignancy

China
Priv.-Doz. Dr. med. Joachim Rom

Completed

Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer

Epithelial Ovarian Cancer

Germany
Calimmune, Inc.

Completed

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

Human Immunodeficiency Virus

United States
M.D. Anderson Cancer Center

Completed

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Myelofibrosis

United States
Swiss Pediatric Oncology Group
ALL SCTped Forum

Recruiting

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

Acute Lymphoblastic Leukemia

Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia

Leukemia

United States
Saladax Biomedical, Inc.

Not yet recruiting

Busulfan Sample Collection Study

Subjects Treated With Busulfan
Nantes University Hospital

Completed

Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies (ITT 08-01)

Hematological Malignancies

France
Nationwide Children's Hospital

Terminated

A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

Sickle Cell Disease

United States
Ruijin Hospital

Recruiting

Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS

Myelodysplastic Syndromes | Myelodysplastic Syndrome With Excess Blasts-2 | Myelodysplastic Syndrome With Excess Blasts-1

China
The Korean Society of Pediatric Hematology Oncology

Completed

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)

Wiskott-Aldrich Syndrome

Korea, Republic of
Jacqueline Garcia, MD
National Institutes of Health (NIH)

Recruiting

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Hematopoietic Stem Cell Transplant | MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)

United States
Columbia University

Active, not recruiting

Stem Cell Transplant in Sickle Cell Disease and Thalassemia

Sickle Cell Disease | Beta Thalassemia

United States
Sichuan University

Recruiting

Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies

Myeloid Malignancies

China
Columbia University

Terminated

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

Neuroblastoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Janssen Research & Development, LLC

Completed

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

Major Depressive Disorder

United States
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)

Lymphoma | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Mixed Phenotype Acute Leukemia

United States
Columbia University

Terminated

Reduced Intensity AlloSCT in(CML) With Persistent Disease (CML)

Chronic Myeloid Leukemia

United States
Baylor College of Medicine

Terminated

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO (THALLO)

Thalassemia

United States
Baptist Health South Florida

Withdrawn

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies (2019-KOE-001)

Acute Myeloid Leukemia | Hematologic Diseases | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Hematologic Malignancy | Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States
Institut Paoli-Calmettes

Unknown

Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes (CEREAL)

Leukemia, Myeloid, Acute | Leukemia, Lymphoblastic, Acute

France
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)

Terminated

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Fanconi Anemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Diamond-blackfan Anemia

United States
Zou Dehui
Juventas Cell Therapy Ltd.

Active, not recruiting

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Large B-cell Lymphoma

China
Northside Hospital, Inc.
Blood and Marrow Transplant Group of Georgia

Completed

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
University of Michigan Rogel Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Multiple Myeloma | Plasma Cell Leukemia

United States
Italian Sarcoma Group

Completed

Protocol for the Treatment of Metastatic Ewing Sarcoma (EW-2)

Ewing's Sarcoma (ES)

Italy

Search clinical trials for: Busulfan/Cyclophosphamide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations